Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
- Umeå University
- University of Minnesota
- University of Washington
- Nencki Institute of Experimental Biology
- Heidelberg University
- University of North Carolina at Chapel Hill
- Wageningen University & Research
- Baylor College of Medicine
- Delft University of Technology (TU Delft)
- Ghent University
- HITS gGmbH
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- Icahn School of Medicine, CABCT
- Josep Carreras Leukaemia Research Institute (IJC)
- KU LEUVEN
- Max Planck Institute of Molecular Cell Biology and Genetics, Dresden
- Northeastern University
- Oak Ridge National Laboratory
- Research Center for Molecular Medicine (CeMM), ÖAW
- Rutgers University
- Stanford University
- The International Institute of Molecular Mechanisms and Machines Polish Academy of Sciences
- The University of North Carolina at Chapel Hill
- The University of South Dakota
- UNIVERSITY OF HELSINKI
- UNIVERSITY OF VIENNA
- University Hospital Magdeburg
- University of Colorado
- University of Oslo
- 19 more »
- « less
-
Field
-
understand the pathogenesis of inflammatory bowel disease (IBD) and developing gene editing therapies for IBD. The role will include working with IBD patient-derived organoids, advancing human in vitro assays
-
signaling, immunology, or host‑pathogen interactions. Experience with in vivo mouse models and mammalian cell culture. Proficiency in molecular biology techniques (cloning, qPCR, Western blotting, gene
-
). Prior experience with gene editing and/or cell engineering (e.g. CRISPR/Cas or related techniques - essential). Expertise with mammalian cell culture is desirable (but not mandatory, a strong background
-
with cutting-edge functional genomics approaches from ChIP-seq, CUT&RUN, massively parallel reporter assays and Hi-C to advanced CRISPR-based approaches for genome editing, single-cell perturbation
-
specializes in precision cardiovascular medicine, leveraging cutting-edge approaches such as human iPSC-derived 2D cardiovascular cells, 3D vascularized cardioids, CRISPR gene editing, high-throughput CRISPRko